³¨½¼³¨³½­°Às·|

 §ä¦^±K½X
 ¥[¤J§Ú­ÌµL¨p¤À¨É




¤½¯q¼s§i¡G­n¬Ù¿ú¡I§ÙµÒª½±µ¬Ù«Ü¤j¡Iµo¹F³Ì§Ö²Ä¤@¨B
¬d¬Ý: 2615|¦^´_: 5
¥´¦L ¤W¤@¥DÃD ¤U¤@¥DÃD
¦¬°_¥ª°¼

¨§¼ß¹w¨¾¨ÅÀù¡£½Ð±N¦¹°T®§§i¶D¨­Ã䪺¤k©ÊªB¤Í¡¤

 Ãö³¬ [½Æ»sÃì±µ]
¸õÂà¨ì«ü©w¼Ó¼h
¼Ó¥D
µoªí©ó 2007-6-3 12:42:01 | ¥u¬Ý¸Ó§@ªÌ ¦^©«¼úÀy |­Ë§ÇÂsÄý |¾\Ū¼Ò¦¡
¨§¼ß¡£½Ð±N¦¹°T®§§i¶D¨­Ã䪺¤k©ÊªB¤Í¡¤®Ú¾Ú³Ìªñ¥l¶}ªº¬ü°êÀù¯g¬ã¨s¨ó·|ACRE·|ij¡]American AssociationforCancer Research¡^¨Ó¦Û¼w¦{University of Texas Medical Branching Galvestonªº¬ã¨sªÌ¿cÄR¬Ã¡]Ķ­µ Lee-JaneLu¡^©Ò°µªº¤T½g¬ã¨s½×¤å«ü¥X: ¸g±`³Ü¨§¼ßªº°ü¤kÅ餺ªº¤k©Ê²üº¸»X»Û©Ê¯À estrogen»P¶ÀÅé¯Àprogesterone³£©úÅã¦a­°§C¡C §Ú­Ì¤wª¾»Û©Ê¯Àªº¿@«×¹L°ª»P¨ÅÀù«Ü¦³Ãö«Y¡A¨ÅÀùªºµo®i»P¤k©Ê²üº¸»X®§®§¬ÛÃö¡C ¬ã¨s¤¤Åý°ü¤k¨C¤Ñ³Ü¤U¬ù1000c.c.ªº¨§¼ß¡A³sÄò¹F¤­­Ó¤ë¡Aµ²ªG³Ü¨§¼ßªº°ü¤kÅ餺ªº»Û©Ê¯À¿@«×¤ñ¤£³Ü¨§¼ßªÌ§C¤F30-40%¡A ¶À¨§¤¤¤wª¾¦³¤@ºØ¤ÑµMªº¤k©Ê²üº¸»XºÙ¤§¬° soflavone¡]²§¶Àଡ^¥¦»P¤HÅ骺²üº¸»X«Ü¬Û¹³¡A ¦³½ìªº¬O¡A¥¦¨ã¦³Âù­«ªº¥\®Ä¡A¤£¦ý¯à°÷¥e¾Ú¨ÅÀùªº²üº¸»X¨üÅé(hormone receptor¡^¡AÅý¤HÅ骺²üº¸»XµLªk¨ë¿E¨ÅÀù²Ó­M¡A ¥t¤@¤è­±¤]¯à°÷¹³¤HÅé¦ÛµMªº¤k©Ê²üº¸»X¤@¼Ë¦a¨¾¤î°©½è²¨ÃP¯g¡A³oºØ¥\®Ä©M¤@ºØ§ÜÃĪ«Tamoxifen·¥¬Û¦ü¡C ªF¤è°ü¤k³q±`·|­¹¥Î¤ñ¦è¤è°ü¤k§ó¦hªº¶À¨§¡A¦ý¬OÀHµÛ¶¼­¹²ßºD¦è¤Æ¡A¦~»´¤@½úªºªF¤è¤k©Êµo¥Í¨ÅÀùªº¾÷·|¶V¨Ó¶V°ª¡A ©Î³\³o¤]©M¶À¨§Äá¨ú¶q¶V¨Ó¶V¤Ö¦³Ãö¡C¶â.....¨k¤k©Ê³£·|±o¨ÅÀùªº¡A©Ò¥H¤j®a¦h³Ü¤¤¦¡¤û¥¤---------¨§¼ß

³¨³½ ³¨½¼ ¬ü­¹ ¹q¼v ®È¹C Áʪ« ¤ô±Ú ¹CÀ¸ ¯S»ù ¤á¥~¬¡°Ê ¹ÎÁÊ Äá¼v ¦í±J
¨Fµo
µoªí©ó 2007-6-14 15:34:24 | ¥u¬Ý¸Ó§@ªÌ
¶â!   ¤w§iª¾©P¾D¤k©ÊªB¤Í­n¦h³Ü¨§¼ß.......

¤£µM¤Á°£¤F·|«ó«óªº....¤£¦n¬Ý               
¦^´_

¨Ï¥Î¹D¨ã Á|³ø

§é¹¹
µoªí©ó 2007-9-15 01:20:30 | ¥u¬Ý¸Ó§@ªÌ
³o¬O¨Ì½g¦n¤å³¹§Ú¤]·|§i¶D§Ú¶g¾D£xªB¤ÍÅý¥L£v³£ª¾¹D
¦^´_

¨Ï¥Î¹D¨ã Á|³ø

¦a´à
µoªí©ó 2008-5-15 10:36:04 | ¥u¬Ý¸Ó§@ªÌ
¦­¤W¤@ªM¨§¼ß
±ß¤W¤@ªMÂA¨Å
¦^´_

¨Ï¥Î¹D¨ã Á|³ø

5¼Ó
µoªí©ó 2009-2-5 14:48:57 | ¥u¬Ý¸Ó§@ªÌ
¶â¶â¶â¶â  
§Ú·|Âà¹F  §Ú»{ÃѪº¤k©Ê  ¦³¤H~~!
¦^´_

¨Ï¥Î¹D¨ã Á|³ø

6¼Ó
µoªí©ó 2009-2-5 17:40:20 | ¥u¬Ý¸Ó§@ªÌ
¨§¼ßªº¦n³B«Ü¦h©O¡A¦h³Ü¦h³Ü~~~
¦^´_

¨Ï¥Î¹D¨ã Á|³ø

¤â¾÷ª©|­°Às·|¦h¤¸¤Æ³¨½¼³¨³½¤Ñ¦a

­°Às·|­«­nÁn©ú
¥»¯¸¬°¤@­Ó¦Û¥Ñªº³¨½¼³¨³½°Q½×°Ï°ì¡A¤@¤Á¯d¨¥¤§¨¥½×¥u¥Nªí¯d¨¥ªÌ­Ó¤H·N¨£¡A¨Ã«D¥»ºô¯¸¤§¥ß³õ¡A¥Î¤á¤£À³§¹¥þ«H¿à¤º®e¡A¨ÃÀ³¦Û¦æ§PÂ_¤º®eªº¯u¹ê©Ê¡A¦Ó¥»¯¸¥H§Y®É¤W¸ü¯d¨¥ªº¤è¦¡¹B§@¡A­°Às·| ¹ï©Ò¦³¯d¨¥ªº¯u¹ê©Ê¡B§¹¾ã©Ê¤Î¥ß³õµ¥¡A¤£­t¥ô¦óªk«ß³d¥ô¡A¥Ñ©ó¥»°Q½×°Ï¨ü¨ì¡u§Y®É¤W¸ü¯d¨¥¡v¹B§@¤è¦¡©Ò³W­­¡A¬G¤£¯à§¹¥þºÊ¹î©Ò¦³¯d¨¥¡A­YŪªÌµo²{¦³¯d¨¥¥X²{°ÝÃD¡A½ÐÁpµ¸§Ú­Ì§Ú­Ì±NºÜ¤O°t¦X­×§ï¡C¥B·q§i¨Ï¥ÎªÌ©MŪªÌ¡A ½Ð¤Åµoªí¯A¤Î¬Fªv¡A¦â±¡¡Aµsª©¡A¤H¨­§ðÀ»µ¥¤å³¹¡A­Õ­Y±z¤£¿í¦u¥H¤W³W©w¡A¦Ó²£¥Íªk«ß°ÝÃD¡A«áªG½Ð¦Û¦æ­t³d¡C
Creative Commons License
³¨½¼³¨³½­°Às·|³¡¤ÀµÛ§@ ±Ä¥Î³Ð¥Î CC ©m¦W¼Ð¥Ü-«D°Ó·~©Ê-¸T¤î§ï§@ 2.5 ¥xÆW ±ÂÅv±ø´Ú±ÂÅv.

GMT+8, 2024-11-23 08:55

Powered by Discuz! X3.3

© 2001-2017 Comsenz Inc.

§Ö³t¦^´_ ªð¦^³»³¡ ªð¦^¦Cªí